Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Rating of “Hold” by Brokerages

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have been assigned an average recommendation of “Hold” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $38.33.

A number of equities analysts have issued reports on AMLX shares. SVB Leerink cut Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. Robert W. Baird cut Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Monday, March 11th. Mizuho cut Amylyx Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, March 18th. Deutsche Bank Aktiengesellschaft assumed coverage on Amylyx Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $36.00 target price for the company. Finally, Evercore ISI restated an “in-line” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th.

Amylyx Pharmaceuticals Stock Up 5.1 %

AMLX opened at $2.88 on Thursday. Amylyx Pharmaceuticals has a 12 month low of $2.67 and a 12 month high of $31.77. The company has a fifty day simple moving average of $12.93 and a 200 day simple moving average of $14.91. The stock has a market cap of $195.21 million, a P/E ratio of 4.11 and a beta of -0.66.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.03. Amylyx Pharmaceuticals had a net margin of 12.94% and a return on equity of 12.39%. The business had revenue of $108.45 million during the quarter, compared to analysts’ expectations of $106.40 million. During the same quarter in the prior year, the company earned ($0.65) EPS. On average, equities research analysts expect that Amylyx Pharmaceuticals will post -0.48 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Justin B. Klee sold 5,841 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $16.33, for a total value of $95,383.53. Following the completion of the sale, the chief executive officer now directly owns 2,836,776 shares in the company, valued at approximately $46,324,552.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Justin B. Klee sold 5,841 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $16.33, for a total transaction of $95,383.53. Following the transaction, the chief executive officer now directly owns 2,836,776 shares of the company’s stock, valued at $46,324,552.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gina Mazzariello sold 1,540 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total transaction of $28,844.20. Following the completion of the transaction, the insider now directly owns 81,372 shares in the company, valued at $1,524,097.56. The disclosure for this sale can be found here. Insiders sold 21,674 shares of company stock worth $378,754 in the last quarter. Corporate insiders own 11.80% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. lifted its holdings in Amylyx Pharmaceuticals by 5,980,997.8% in the fourth quarter. Point72 Asset Management L.P. now owns 2,751,305 shares of the company’s stock valued at $40,499,000 after buying an additional 2,751,259 shares during the period. Vanguard Group Inc. increased its position in shares of Amylyx Pharmaceuticals by 253.6% during the third quarter. Vanguard Group Inc. now owns 3,514,356 shares of the company’s stock worth $98,929,000 after acquiring an additional 2,520,355 shares in the last quarter. BlackRock Inc. increased its position in shares of Amylyx Pharmaceuticals by 223.6% during the third quarter. BlackRock Inc. now owns 2,295,834 shares of the company’s stock worth $64,628,000 after acquiring an additional 1,586,402 shares in the last quarter. Stonepine Capital Management LLC grew its position in Amylyx Pharmaceuticals by 124.4% in the 3rd quarter. Stonepine Capital Management LLC now owns 2,515,868 shares of the company’s stock worth $46,066,000 after purchasing an additional 1,394,840 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in Amylyx Pharmaceuticals by 121.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,700,200 shares of the company’s stock worth $31,131,000 after purchasing an additional 932,000 shares in the last quarter. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.